Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression

To see complete record on, please visit this link

Id: NCT01627782

Organisation Name: Janssen Research & Development, LLC

Overal Status: Completed

Start Date: August 6, 2012

Last Update: June 2, 2020

Lead Sponsor: Janssen Research & Development, LLC

Brief Summary: The purpose of this study is to explore the optimal dose frequency of ketamine in patients with treatment-resistant depression (TRD).

  • Major Depressive Disorder

Total execution time in seconds: 0.31497812271118